LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES

LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES

Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017. If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. IT’S ALL ABOUT INFLAMMATION AND OXIDATION.

TRANSMISSION OF INFECTIOUS DISEASE DURING AIR TRAVEL

TRANSMISSION OF INFECTIOUS DISEASE DURING AIR TRAVEL

Director of CDC said “there is zero risk of transmission of Ebola on air flight.”  That’s not true.  Ebola spreads in humans and primates by aerosol transmission and also by direct contact with blood, mucus or other fluids from an infected person.  These viruses have longer incubation periods, making infected passengers potentially symptom-free and unaware that they are infected at the time of travel even though they can spread disease by droplet transmission.